Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
Progressive cGVHD
CUI: C3539781
Disease: Progressive cGVHD
0.100 GeneticVariation BEFREE In conclusion, the real-world clinical adoption of the combination approach with both tissue rebiopsy and liquid biopsy for T790M genotyping may provide significant benefits to patients who have developed PD after first-generation TKI treatments. 30927306 2019
Progressive cGVHD
CUI: C3539781
Disease: Progressive cGVHD
0.100 GeneticVariation BEFREE The presence of an EGFRm (excluding T790M) was associated with untreated or progressive disease, p = 0.04. 31027703 2019
Progressive cGVHD
CUI: C3539781
Disease: Progressive cGVHD
0.100 GeneticVariation BEFREE The incidence of <i>EGFR</i> T790M tended to be higher among patients with CNS PD than in those without CNS PD, although the difference was not statistically significant (66.7% <i>vs.</i> 40.4%; P=0.23). 31179076 2019
Progressive cGVHD
CUI: C3539781
Disease: Progressive cGVHD
0.100 GeneticVariation BEFREE Total duration of EGFR-TKI treatment before rebiopsy, TKI-free interval, EGFR-TKI treatment history immediately before rebiopsy, continuation of initial EGFR-TKI beyond progressive disease, progression-free survival after initial TKI treatment, and rebiopsy site (other than fluid samples) significantly influenced T790M status. 28866043 2018
Progressive cGVHD
CUI: C3539781
Disease: Progressive cGVHD
0.100 GeneticVariation BEFREE Osimertinib was approved by the US Food & Drug Administration in November 2015 for patients whose tumors exhibited T790M mutation and for those with progressive disease on other EGFR TKIs. 28367058 2017
Progressive cGVHD
CUI: C3539781
Disease: Progressive cGVHD
0.100 GeneticVariation BEFREE A total of 4 of the 5 patients with a history of T790M positivity based on plasma DNA levels had PD. 28588734 2017
Progressive cGVHD
CUI: C3539781
Disease: Progressive cGVHD
0.100 GeneticVariation BEFREE However, the levels of the EGFR exon 19 deletion driver mutation and the T790M resistance mutation in the circulating tumor DNA continued to rise and the patient died from progressive disease 6 weeks after commencement of combination therapy. 28843359 2017
Progressive cGVHD
CUI: C3539781
Disease: Progressive cGVHD
0.100 GeneticVariation BEFREE T790M was detected in 14/29 patients (48.3%) with a partial response to afatinib, 1/4 patients (25%) with stable disease, and 1/4 patients (25%) with progressive disease as the best response. 28978102 2017
Progressive cGVHD
CUI: C3539781
Disease: Progressive cGVHD
0.100 GeneticVariation BEFREE Dividing into four periods (before PD, at PD, at discontinuation of EGFR-TKI and subsequently), T790M was detected in 10, 19, 24 and 27% of patients, respectively. 26577492 2016
Progressive cGVHD
CUI: C3539781
Disease: Progressive cGVHD
0.100 GeneticVariation BEFREE Almost half of the T790M ctDNA positive patients were identified at a median time of 2.2 months prior to clinically progressive disease (PD). 26867973 2016
Progressive cGVHD
CUI: C3539781
Disease: Progressive cGVHD
0.100 GeneticVariation BEFREE EGFR T790M was identified from plasma DNA in 54% (15 of 28) of patients with prior clinical response to gefitinib/erlotinib, 29% (4 of 14) with prior stable disease, and in 0% (0 of 12) that had primary progressive disease or were untreated with gefitinib/erlotinib. 19351754 2009